<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is ranked among the top leading causes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> in industrialized populations </plain></SENT>
<SENT sid="1" pm="."><plain>Polycomb group proteins, including Suz12 and Ezh2, are epigenetic regulatory proteins that act as transcriptional repressors of many differentiation-associated genes and are overexpressed in a large subset of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="2" ids="26536">Retinoic acid</z:chebi> (RA) acts as a negative regulator of PcG actions in stem cells, but has shown limited therapeutic potential in some <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, in part because of <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> receptor Î² silencing </plain></SENT>
<SENT sid="3" pm="."><plain>Through treatment with RA, Suz12 shRNA knockdown, or Ezh2 pharmacological inhibition with 3-deazaneplanocin A (DZNep), we increased TRAIL-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>This <z:mp ids='MP_0006042'>increased apoptosis</z:mp> in human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells after RA or DZNep treatment was associated with a ~2.5-fold increase in TNFRSF10B (DR5) transcript levels and a 42% reduction in the H3K27me3 epigenetic mark at the TNFRSF10B promoter after DZNep addition </plain></SENT>
<SENT sid="5" pm="."><plain>Taken together, our findings indicate that pharmacological inhibition of Polycomb repressive complex 2 histone methyltransferase activity may constitute a new epigenetic therapeutic strategy to overcome RA non-responsiveness in a subset of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> by increasing TRAIL-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> sensitivity </plain></SENT>
</text></document>